Marshall Wace’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16M Sell
794,317
-970,521
-55% -$26.1M 0.01% 776
2026
Q2
$44.7M Buy
1,764,838
+1,688,651
+2,216% +$37.2M 0.04% 418
2026
Q1
$1.7M Sell
76,187
-417,192
-85% -$10M ﹤0.01% 1875
2025
Q4
$13.2M Sell
493,379
-1,865,502
-79% -$44.6M 0.01% 773
2025
Q3
$50.3M Buy
2,358,881
+389,170
+20% +$9.2M 0.05% 314
2025
Q2
$42.5M Buy
1,969,711
+1,639,315
+496% +$30.5M 0.05% 338
2025
Q1
$5.49M Sell
330,396
-663,197
-67% -$12M 0.01% 1018
2024
Q4
$18.2M Sell
993,593
-195,019
-16% -$3.15M 0.02% 578
2024
Q3
$18.3M Sell
1,188,612
-1,585,741
-57% -$26.5M 0.02% 536
2024
Q2
$45.1M Buy
2,774,353
+2,251,940
+431% +$36.3M 0.06% 285
2024
Q1
$9.7M Buy
+522,413
New +$12.9M 0.01% 758
2023
Q4
– Sell
-941,755
Closed -$19.6M – 2114
2023
Q3
$19.6M Buy
941,755
+916,903
+3,689% +$24.9M 0.04% 446
2023
Q2
$595K Buy
+24,852
New +$552K ﹤0.01% 1924
2022
Q2
– Sell
-532,557
Closed -$12.9M – 3366
2022
Q1
$12.9M Buy
+532,557
New +$12.9M 0.02% 704
2021
Q1
– Sell
-848,679
Closed -$45.4M – 2412
2020
Q4
$45.4M Sell
848,679
-285,133
-25% -$14.2M 0.25% 85
2020
Q3
$46.8M Buy
1,133,812
+933,686
+467% +$40.3M 0.3% 73
2020
Q2
$9.7M Buy
+200,126
New +$9.6M 0.07% 293
2016
Q2
– Sell
-37,174
Closed -$1.04M – 965
2016
Q1
$1.04M Buy
+37,174
New +$811K 0.01% 700
2015
Q2
– Sell
-22,686
Closed -$739K – 879
2015
Q1
$739K Buy
+22,686
New +$780K 0.01% 622

Other funds holding ACAD

Marshall Wace's ACAD Position: Q3 2026 in Review

Marshall Wace reduced its Acadia Pharmaceuticals (ACAD) stake by 55% in Q3 2026, selling an estimated $26.1M and leaving 794,317 shares worth $16M. The position accounts for 0.01% of the portfolio, ranked #776.

Marshall Wace first reported a position in ACAD in Q1 2015 and has held it in 19 quarters since. The position peaked at $50.3M in Q3 2025. 346 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Marshall Wace held 794,317 shares of Acadia Pharmaceuticals worth $16M as of Q3 2026.
  • Marshall Wace sold 970,521 Acadia Pharmaceuticals shares in Q3 2026, an estimated $26.1M.
  • Acadia Pharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q3 2026, its #776 holding.
  • Marshall Wace first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 19 quarters since.
  • Marshall Wace's Acadia Pharmaceuticals position peaked at $50.3M in Q3 2025.
  • 346 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.